• Key priority of mucoactive therapy efficiency in children with bronchopulmonary diseases (a literature review)

Key priority of mucoactive therapy efficiency in children with bronchopulmonary diseases (a literature review)

SOVREMENNAYA PEDIATRIYA.2017.4(84):41-47; doi 10.15574/SP.2017.84.41

Okhotnikova E., Ponochevna E.
Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine

The high prevalence of the lower respiratory tract diseases in children is determined by the respiratory system anatomical and functional properties and high burdened allergic history. Violation of the physiological process of airway clearing is observed in case of both excessive expectoration and insufficient phlegm production. The standard treatment of diseases associated with cough is etiological treatment that includes antitussive drugs or expectorants. Pektolvan C is involved in a local immune response, effective in an acute phase of inflammation, well-tolerated and safety, improves the terms of recovery reduction.

Key words: cough, children, mucolytic agents, Pektolvan С.

References

1. Bereznyakov IG. (1998). Kashel: diagnostika i lechenie. Lektsiya dlya vrachey. Kiev: 28.

2. Buryak VN. (2014, ver). Osobennosti terapevticheskoy taktiki pri ostrom bronhite u detey. Zdorovia Ukrainy. Tematychnyi nomer: 44—45.

3. Horlenko OM, Aleksandrov OIu, Aleksandrova MIa. (2006). Kashel yak symptom, shliakhy korektsii. Klinichna imunol Alerhol Infektol. 2(03): 51—54.

4. Marushko YuV, Hyshchak TV, Myka MIu, Marushko YeIu. (2015, hrud). Dosvid zastosuvannia preparatu Pektolvan Ts v kompleksnii terapii bronkholehenevykh zakhvoriuvan u ditei. Zdorovia Ukrainy. Tematychnyi nomer: 48—50.

5. Zaytseva OV. (2003). Mukoliticheskie preparatyi v terapii bolezney organov dyihaniya u detey: sovremennyiy vzglyad na problemu. RMZh. 11; 1: 40—42.

6. Zubarenko AV, Gurienko EA, Gornostaeva NYu. (2011). Novyie podhodyi v lechenii kashlya u detey s ispolzovaniem rastvora Flavamed. Klinichna pediatriia. 1(28): 32—36.

7. Kryvopustov SP. (2017). Kombinovana mukoaktyvna terapiia zakhvoriuvan dykhalnykh shliakhiv u ditei, shcho suprovodzhuiutsia utvorenniam viazkoho sekretu. Zdorove rebenka. 12; 2: 33—35.

8. Maidannyk VH. (2005). Komentar do protokoliv likuvannia hostrykh bronkhitiv u ditei. Pediatriia, akusherstvo ta hinekolohiia. 5: 45—48.

9. Ovcharenko SI. (2002). Mukoliticheskie (mukoregulyatornyie) preparatyi v lechenii hronicheskoy obstruktivnoy bolezni legkih. RMZh. 10; 4: 23—27.

10. Ponochevna OV. (2014). Efektyvnist vykorystannia Pektolvanu Ts v terapii zakhvoriuvan nyzhnikh dykhalnykh shliakhiv infektsiinoho ta alerhichnoho henezu u ditei molodshoho shkilnoho viku. Zbirnyk nauk pr spivrob NMAPO imeni PL Shupyka. 23; 3: 353—357.

1. Soroka YuA, Prohorova IN. (2010). Mukoliticheskaya terapiya v pediatricheskoy praktike. Klinichna pediatriia. 1(22): 9—15.

12. Strachunskiy LS, Belousov YuB, Kozlova SN. (2000). Antibakterialnaya terapiya. Prakticheskoe rukovodstvo. Moskva: 89—90.

13. Chuchalin AG, Abrosimov VN. (2000). Kashel. Ryazan: 5—9.

14. Paleari D, Rossi GA, Nicolini G et al. (2011). Ambrosial: a multifaceted molecule with additional therapeutic potentials in respiratory disorders of childhood. Expert Opin. Drug Discov. 6(11): 1203—1214. https://doi.org/10.1517/17460441.2011.629646; PMid:22646987

15. Braga PC, Scaglione F, Scarpazza G et al. (1985). Comparison between penetration of amoxicillin combined with carbocysteine and amoxicillin alone in pathological bronchial secretions and pulmonary tissue. Int J Clin Pharmacol Res. 5(5): 33—40.

16. Malerba M, Ragnoli B. (2008). Ambroxol in the 21st century: pharmacological and clinical update. Expert Opin Drug Metab Toxicol. 4(8): 1119—1129. https://doi.org/10.1517/17425255.4.8.1119; PMid:18680446

Содержание журнала Full text of article